Lilly's Cyramza misses liver-cancer target

Share this article:

Eli Lilly's gastric cancer drug Cyramza, previously known as ramucirumab, failed to hit its Phase-III targets among liver-cancer patients using the drug as a second-line treatment. The Wall Street Journal reports that although Cyramza patients had more favorable overall survival rates than placebo patients, the differences were not statistically significant.

The drug failed to hit targets in a breast cancer clinical trial last year, but showed promise in Phase-III tests among non-small cell lung cancer patients when used with docetaxel.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.